Lou Gehrig's Disease News and Research RSS Feed - Lou Gehrig's Disease News and Research

Lou Gehrig's Disease or Amyotrophic Lateral Sclerosis (ALS) is a neurological disorder characterized by progressive degeneration of motor neuron cells in the spinal cord and brain, which ultimately results in paralysis and death. The disease takes its less-scientific name from Lou Gehrig, a baseball player with the New York Yankees in the late 1920s and 1930s, who was forced to retire in 1939 as a result of the loss of motor control caused by the disease.

In 1991, a team of researchers linked familial ALS to chromosome 21. Two years later, the SOD1 gene was identified as being associated with many cases of familial ALS. The enzyme coded for by SOD1 carries out a very important function in cells: it removes dangerous superoxide radicals by converting them into non-harmful substances. Defects in the action of this enzyme mean that the superoxide radicals attack cells from the inside, causing their death. Several different mutations in this enzyme all result in ALS, making the exact molecular cause of the disease difficult to ascertain.

Recent research has suggested that treatment with drugs called antioxidants may benefit ALS patients. However, since the molecular genetics of the disease are still unclear, a significant amount of research is still required to design other promising treatments for ALS.
New treatment could stop progression of ALS

New treatment could stop progression of ALS

Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, for nearly two years in one type of mouse model used to study the disease - allowing the mice to approach their normal lifespan. [More]
Researchers identify protein that could protect against toxic degeneration of cells in ALS

Researchers identify protein that could protect against toxic degeneration of cells in ALS

J. Gavin Daigle, a PhD candidate at the LSU Health New Orleans School of Graduate Studies, is the first author of a paper whose findings reveal another piece of the Amyotrophic Lateral Sclerosis (ALS) puzzle. [More]
NIH-funded analysis identifies three genes that contribute to most common form of glaucoma

NIH-funded analysis identifies three genes that contribute to most common form of glaucoma

An analysis funded by the National Eye Institute (NEI), part of the National Institutes of Health, has identified three genes that contribute to the most common type of glaucoma. The study increases the total number of such genes to 15. [More]
St. Jude scientists develop interactive tool to advance understanding of mutations that fuel pediatric cancer

St. Jude scientists develop interactive tool to advance understanding of mutations that fuel pediatric cancer

St. Jude Children's Research Hospital scientists have developed a web application and data set that gives researchers worldwide a powerful interactive tool to advance understanding of the mutations that lead to and fuel pediatric cancer. The freely available tool, called ProteinPaint, is described in today's issue of the scientific journal Nature Genetics. [More]
Scientists pin down structure of neuronal protein clumps associated with ALS

Scientists pin down structure of neuronal protein clumps associated with ALS

To create treatments for a disease without any, scientists need to study and understand the driving forces behind the faulty biology. Today, researchers at the University of North Carolina School of Medicine announced the first-ever evidence-based description of the neuronal protein clumps thought to be important in Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, a fatal neurodegenerative condition. [More]
Utah chemists devise new way to detect DNA damage

Utah chemists devise new way to detect DNA damage

University of Utah chemists devised a new way to detect chemical damage to DNA that sometimes leads to genetic mutations responsible for many diseases, including various cancers and neurological disorders. [More]
OSU discovery sheds new light on how proteins fold

OSU discovery sheds new light on how proteins fold

Biochemists at Oregon State University have made a fundamental discovery about protein structure that sheds new light on how proteins fold, which is one of the most basic processes of life. [More]
Research highlights potential new treatment strategy for degenerative diseases

Research highlights potential new treatment strategy for degenerative diseases

St. Jude Children's Research Hospital scientists have discovered evidence of a mechanism at the heart of amyotrophic lateral sclerosis (ALS) and related degenerative diseases. The research appears in today's edition of the journal Cell and highlights a possible new treatment strategy for the devastating disorders. [More]
HSCI researchers find surprising similarities between SMA and ALS

HSCI researchers find surprising similarities between SMA and ALS

Harvard Stem Cell Institute researchers studying spinal muscular atrophy (SMA) have found what they term "surprising similarities" between this childhood disorder that attacks motor neurons and amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease. [More]
Endothelin system offers potential therapeutic target for ALS

Endothelin system offers potential therapeutic target for ALS

Amyotrophic lateral sclerosis (ALS) is a disorder in which cells of the nervous system die, leading to muscle weakness that impacts breathing, movement and other physical functions. [More]
Two studies highlight important new discovery around most common genetic defect linked to ALS

Two studies highlight important new discovery around most common genetic defect linked to ALS

In today's issue of Nature, two new studies funded in part by The ALS Association both highlight an important new discovery around the C9orf72 mutation, the most common genetic defect associated with amyotrophic lateral sclerosis (ALS). [More]
Scientists reveal how a common gene mutation in ALS and FTD disrupts normal cell function

Scientists reveal how a common gene mutation in ALS and FTD disrupts normal cell function

Researchers have determined how the most common gene mutation in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) disrupts normal cell function, providing insight likely to advance efforts to develop targeted therapies for these brain diseases. [More]
FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company's resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults. [More]
Study suggests potential target for treating familial form of ALS

Study suggests potential target for treating familial form of ALS

A healthy motor neuron needs to transport its damaged components from the nerve-muscle connection all the way back to the cell body in the spinal cord. If it cannot, the defective components pile up and the cell becomes sick and dies. Researchers at the NIH's National Institute of Neurological Disorders and Stroke have learned how a mutation in the gene for superoxide dismutase 1 (SOD1), which causes ALS, leads cells to accumulate damaged materials. [More]
Brain-controlled prosthesis could improve quality of life in people with spinal cord injuries

Brain-controlled prosthesis could improve quality of life in people with spinal cord injuries

When we type or perform other precise tasks, our brains and muscles usually work together effortlessly. But when a neurological disease or spinal cord injury severs the connection between the brain and limbs, once-easy motions become difficult or impossible. [More]

ALS Ice Bucket Challenge making splash again this August

Led by co-founders Pete Frates, Pat Quinn and Anthony Senerchia, and with the help of celebrities, the Boston Red Sox and Major League Baseball, the ALS Ice Bucket Challenge is making a splash again this August. [More]
Natural protein fragment produced in the brain can inhibit enzyme implicated in Alzheimer's disease

Natural protein fragment produced in the brain can inhibit enzyme implicated in Alzheimer's disease

For the first time, UCLA researchers have shown that a natural protein fragment produced in the brain can act as an inhibitor of a key enzyme implicated in the onset of Alzheimer's disease, a finding that could lead to the development of new drugs to treat the disease. [More]
Key differences identified among patients with ALS

Key differences identified among patients with ALS

Researchers on Mayo Clinic's Florida campus have identified key differences between patients with sporadic amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and those with the most common genetic form of ALS, a mutation in the C9orf72 gene. [More]
Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the development of groundbreaking drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), announced today that Robert G. Miller, M.D., Director of the Forbes Norris MDA/ALS Research Center at Sutter Health's California Pacific Medical Center in San Francisco, has been awarded a grant from The ALS Association for $1.5 million to help fund a Phase 2 clinical study of the company's investigational therapy for ALS, NP001. [More]

ALS ACT initiative to speed discovery of new ALS treatments

The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) initiative. [More]
Advertisement
Advertisement